** Shares in Galderma GALD.S rise 5.7% after the company posted Q1 results that beat expectations, driven by higher sales, especially in its Injectable Aesthetics division
** Sales in Injectable Aesthetics were up 9.9% y/y, which analysts at Jefferies and J.P. Morgan point to as 6% above consensus, driven primarily by Neuromodulators sales
** U.S. sales did not reach consensus expectations but this was offset by "pleasing double-digits" growth in international sales, Vontobel says
** The U.S. sales launch of atopic dermatitis and prurigo nodularis medication Nemluvio was stronger than expected, analysts say, with Jefferies seeing the trajectory as "promising when compared to Sanofi SASY.PA/Regeneron's REGN.O Dupixent and Eli Lilly's LLY.N Ebglyss"
** Up to the previous session's close, shares were down 19.9% YTD
(Reporting by Bernadette Hogg)
((bernadette.hogg@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.